Pfizer is rated a Buy with 55%+ upside potential, driven by a robust pipeline and undervalued forward earnings. Read more on ...

Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is back in focus after recent share price moves, with the stock closing at $26.04. For investors, the key question is how this current level ...

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts ...

As the short list of problems above highlights, Pfizer is not hitting on all cylinders right now. Wall Street knows this, which helps explain why the pharmaceutical company's stock has fallen more ...

News flow from Pfizer (PFE) has been seemingly light in the last few months, at least in terms of importance and share price impact, but a lot has been going on under the surface.There is not much the ...

Pfizer'sPFE "mild" first-quarter report is unlikely to satisfy skeptics, an expert said Tuesday as Pfizer stock dipped despite the drugmaker beating sales and profit expectations. The holdback? Covid.

Following its June 18, 2026 announcement of a Chief Financial Officer transition, Pfizer reaffirmed the full-year 2026 financial guidance it first issued on December 16, 2025 and reiterated on May 5, ...

One of them seems to have made more progress on that front.

Stock index futures were higher on Tuesday as tech stocks continued to recover, with the SpaceX IPO set for Friday. Here are ...